{'fraction_non_alphanumeric': 0.01649746192893401, 'fraction_numerical': 0.0, 'mean_word_length': 5.414634146341464, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Generic medicines--how confident should we be?

The scientific and clinical robustness of bioequivalence is frequently challenged by health professionals, patients, media and sections of the pharmaceutical industry. Generic medicines rely on being bioequivalent to gain a share of the market once a branded product reaches the end of its patent life. In all countries, the lower prices of generic products provide an important opportunity to reduce the costs of healthcare without reducing quality. In countries such as Fiji with an essential medicines list, the products that are sourced are frequently generic brands. It is therefore essential that health professionals, governments and the broader community are confident in the quality and clinical effectiveness of generic medicines.